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Abstract
Isoflurane is a popular volatile anesthetic agent used in humans as well as in experimental animal research. In previous
animal studies of the blood-brain barrier (BBB), observations towards an increased permeability after exposure to isoflurane
are reported. In this study we investigated the effect of a 2-hour isoflurane exposure on apoptosis of the cerebral
endothelium following 24 hours of hypoxia in an in vitro BBB model using astrocyte-conditioned human umbilical vein
endothelial cells (AC-HUVECs). Apoptosis of AC-HUVECs was investigated using light microscopy of the native culture for
morphological changes, Western blot (WB) analysis of Bax and Bcl-2, and a TUNEL assay. Treatment of AC-HUVECs with
isoflurane resulted in severe cellular morphological changes and a significant dose-dependent increase in DNA
fragmentation, which was observed during the TUNEL assay analysis. WB analysis confirmed increases in pro-apoptotic
Bax levels at 4 hours and 24 hours and decreases in anti-apoptotic Bcl-2 in a dose-dependent manner compared with the
control group. These negative effects of isoflurane on the BBB after a hypoxic challenge need to be taken into account not
only in experimental stroke research, but possibly also in clinical practice.
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Introduction
Isoflurane is a widely used hypnotic volatile anesthetic agent
used in both the clinic and experimental animal research. In
human stroke, however, anesthesia is not desired in order to
retain the patient’s conscience and cooperation for neurological
follow-up while in experimental stroke research anesthetic
regime are the rule to induce cerebral ischemia by i.e. middle
cerebral artery occlusion. In the last decade the concept of the
neurovascular unit (NVU) as an integrative system of endothe-
lial cells, astrocytes, neurons, microglia, pericytes and their
respective functions has emerged, challenging the classical
neurocentric concept of brain ischemia [1,2,3]. In addition,
neuroprotective drugs appear to have differing, that is delete-
rious or beneficial effects, depending on the time of adminis-
tration within the transition from injury to repair at the NVU
[4]. Longitudinal stroke studies using non-invasive imaging are
particularly suited to assess time specific effects of drug therapy,
and enable comparison to the human situation – especially
magnetic resonance imaging (MRI) with imaging sequences
similar or close to the human brain [5,6]. However, surveillance
of experimental stroke requires repetitive anesthesia for MRI,
and this effect on stroke evaluation and outcome as well as
interaction to the drug tested is ill characterized but of great
importance. Isoflurane has been linked to a variety of effects on
endothelial cells, which in the brain represent an essential part
of the blood-brain barrier (BBB). Amongst those effects are
BBB leakage for macromolecules such as albumin and vasodi-
latation – effects that ultimately influence stroke outcome
[7,8,9,10,11].
In a recently published stroke study characterizing the
biphasic BBB opening following ischemia and reperfusion using
serial MRI including T2-relaxometry and post-contrast T1-
sequences to assess BBB permeability, we observed progressive
cerebral contrast enhancement in the ischemic and non-
ischemic brain [12]. This finding is suggestive of para-
endothelial contrast agent extravasation through a defective
BBB tight-junction complex. An additional rodent study by Hu
and coworkers raises further concerns about harmful effects of
isoflurane applied subsequent to focal brain ischemia and
reperfusion [13].
In the present study using an in vitro BBB model, astrocyte-
conditioned human umbilical vein endothelial cells (AC-HU-
VECs) were subjected to increasing doses of isoflurane both under
normoxic conditions and subsequent to sustained hypoxia. We
demonstrate that isoflurane induces apoptosis and that this effect is
potentiated by hypoxia. These findings are highly relevant to the
choice of anesthesia in experimental research and potentially also
in the clinical setting.
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In Vitro Model of the BBB
A primary cell culture of HUVECs harvested from donor
umbilical cords was stored in liquid nitrogen at 2197uC, as
previously published [14,15]. The cells were plated on gelatin-
coated tissue cell culture flasks and grown to the first confluence in
an atmosphere of 5% CO2/95% air at 37uC. The cell culture
medium consisted of endothelial cell growth medium (ECGM,
Provitro, Berlin, Germany) supplemented with 0.02 ng/L endo-
thelial cell growth factor (Provitro), 5% fetal cattle serum (Sigma
Aldrich, Munich, Germany), and 50 mg/L gentamicin (PPA,
Co ¨lbe, Germany). Experiments were performed using HUVECs
up to passage 5 to minimize the loss of endothelial properties that
occurs during multiple passaging.
To induce transdifferentiation of HUVECs into cerebral
endothelium–like cells with numerous tight junctions, the cells
were grown in 50% (vol/vol) ECGM and 50% astrocytic
conditioned medium (ACM), as previously published [16]. In
brief, the ACM was prepared by culturing cells from the U-87 line
(ATCC, Wesel, Germany), an astrocytic glioblastoma Grade III
cell line, in Dulbecco’s modified Eagle medium, low glucose (1 g/
L) (Sigma Aldrich), supplemented with 10% fetal cattle serum
(Sigma Aldrich), 5 ml 1006 modified Eagle medium vitamins
(PPA), 5 ml nonessential amino acids (PPA), and 5 mg gentamicin
(PPA). The U-87 cells were incubated for 2 days. Following aseptic
aspiration, the ACM was frozen at 280uC until use. Verification
of the transdifferentiation of HUVECs into cerebral endothelium–
like cells was made by measuring the increase in transendothelial
electrical resistance (TEER). For this purpose, HUVECs were
seeded onto semipermeable 0.2-mm porous filter inserts in 6-well
plates (Corning, Kaiserslautern, Germany). After determination of
the baseline resistance of the filter, a culture medium composed of
50% ECGM/50% ACM was added above and below the filter
element. At intervals of 24 h for a period of 7 days, TEER
measurements were made across the monolayer (Millicell ERS,
Millipore, Billerica, MA), and the baseline resistance of individual
filters was subtracted. The TEER results were converted into
specific resistance values by multiplication with the filter area.
Hypoxia
For oxygen deprivation, transdifferentiated HUVECs were
grown to confluence in cell culture flasks with filterless caps, and
placed in a BBD 6220 humidified hypoxia chamber (Thermo
Scientific Heraeus, Langenselbold, Germany) at 3 vol% O2 and 5
vol% CO2, with the cap unsealed. After 1 h of equilibration, the
caps were sealed completely and the tissue flasks were maintained
in the hypoxic atmosphere for an additional 23 h within the
chamber. After 24 h of hypoxia, the caps were opened, and the
flasks were returned to the normoxic incubator to allow
reoxygenation. Following a period of 2 h, the AC-HUVECs were
subjected to isoflurane or control treatment (Figure 1).
Anesthesia Treatment
The AC-HUVECs were treated with the volatile anesthetic
agent isoflurane or control conditions by using a modified
anesthesia unit Trajan 808 (Draeger, Lu ¨beck, Germany), which
delivered compressed air (95%)/CO2 (5%). An anesthesia gas
vapor for the evaporation of isoflurane (Forane, Abbott India,
Verna Salcette, India) was installed. The gas mixture was
conducted into cell culture flasks, and the temperature of the
flasks was maintained at 37uC by placing them on feedback-
regulated heated gel pads. The gas composition in the culture
flasks was continuously monitored using a Capnomak Ultima
monitor (Datex Engstrom, Fairfield, CT, United States). The AC-
HUVECs were treated according to a study protocol with
isoflurane concentrations of 0 (control), 0.5, 1, or 2 minimal
alveolar concentrations (MAC) for 2 h. One MAC was considered
1.3 vol%. After the treatment period, the anesthetic agent was
washed out with 95% air/5% CO2 for 30 min. Control
experiments were performed in the same manner, but without
adding isoflurane to the gas mixture. Afterwards, the culture flasks
were returned to the incubator for a recovery period of either 4 or
24 h before harvesting and analysis (see Figure 1 for a diagram of
the study design).
TUNEL Staining and Microscopy
To estimate the degree of apoptosis, we used the terminal
deoxynucleotidyl (TdT)–mediated dUTP-biotin nick end labeling
(TUNEL) technique (n=2 independent experiments per group).
For this, AC-HUVECs were grown on cover glasses until
confluence. After they had been exposed to isoflurane or control
conditions and allowed the recovery period, the cells were fixed
with 4% paraformalin solution. Following permeabilization of the
samples with Triton X100 0.1% (100 ml per cover slip), staining
was performed using an In-situ Cell Death Detection Kit
(Fluorescein 116847959-10 kit, Roche, Mannheim, Germany).
The read-out was performed using a fluorescence microscope
(Leica DM RBC, Leica Microsystems, Wetzlar, Germany)
equipped with an EBQ 100 fluorescence detector (Leica Micro-
systems) at an emission wavelength of 565 nm; absolute fluores-
cence intensities were recorded by the FM Visi View software (V
2.0.3, Leica Microsystems) under identical microscopic settings
(28 ms exposure time, 40 times magnification). Per slide, three
pictures allocated in a pre-defined manner were taken, and the
mean of overall image fluorescence was used for further
calculations. As positive controls, we used AC-HUVECs that
had been permeabilized with Triton X100 (PAA) for 10 min at
room temperature and treated with 3000 U/ml recombinant
DNAase 1 (Sigma Aldrich) before TUNEL staining.
Western Blot Analysis
Western blot (WB) analysis was performed to investigate
expression of the apoptosis marker Bcl-2–associated X protein
(Bax) and the anti-apoptotic B-cell lymphoma protein 2 (Bcl-2) in
AC-HUVECs (n=3 independent experiments per group) [17,18].




++, Sigma Aldrich) and harvested, and the
cell pellet was lysed on ice using 100 ml RIPA buffer (5 ml Triton
X100 [PAA], EDTA 190 mg [Sigma Aldrich], 0.5 mg SDS
[Sigma Aldrich], and 2.5 g sodium deoxycholate in 500 ml PBS
w/o Ca
++/Mg
++ [PAA]) containing protease inhibitors (cOmplete
ULTRA, Roche) and phosphatase inhibitors (PhosSTOP, Roche)
at a concentration of 1 tablet/ml, respectively. After 30 min of
centrifugation at 8,400 g and 4uC, the protein-rich supernatant
was removed and stored at 280uC until analysis.
For the gel electrophoresis, 10% acrylamide SDS separating
gels (Sigma Aldrich) were prepared. Protein samples were diluted
3:1 with 46 Laemmli buffer. After instilling the electrophoresis
buffer TGS (BioRAD, Munich, Germany), 40 mg of protein per
lane were loaded. Quantification of total protein content was
performed using a BCA test kit (BCA Assay Kit, Thermo Fisher
Scientific GmbH, Ulm, Germany). As a size standard, fluorescent
Page Ruler Prestained Protein Ladder (Fermentas GmbH, St.
Leon-Rot, Germany) was applied. As positive controls, we used
RAW 264.7 (IP) Cell Lysate (SC- 2211, Santa Cruz Biotechnol-
ogy, Heidelberg, Germany) for Bax and WEHI 231 Cell Lysate
(SC- 2213, Santa Cruz) for Bcl-2. After electrophoresis the
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Hybond-CExtra nitrocellulose (Amersham, Bucks, UK). Thereaf-
ter the blots were rinsed three times with 16washing buffer TBS
(Sigma Aldrich) with Tween 20 (PAA) and blocked for 60 min
with milk powder at room temperature. The primary antibody
anti-ß-actin, produced in mouse (A5316, Sigma Aldrich) and
diluted 1:5,000 in blocking buffer (LI-COR Biosciences GmbH,
Bad Homburg, Germany), and the primary antibody anti-Bax or
anti-Bcl-2, produced in rabbit (Cell Signaling, Frankfurt am Main,
Germany) and diluted 1:1000 in LI-COR blocking buffer, were
applied. Blots were incubated for 16 h at 4uC. After rinsing, the
fluorescence-labeled secondary antibodies anti-mouse and anti-
rabbit, produced in donkey (700/800 IRDye, LI-COR) and
diluted 1:15,000 in washing buffer (BioRAD), were added. For
1 h the blots were incubated in darkness at room temperature.
The WBs were read using a blot reader (Odyssey, LI-COR). Bax
and Bcl-2 levels were normalized for ß-actin.
Statistical Analysis
Statistical analysis was performed using PASW Statistics 18
(SPSS Inc., Chicago, IL, US). To compare protein marker levels,
we used the Kruskal-Wallis test; this was followed by the Mann-
Whitney test to compare individual groups and time points. To
confirm a concentration-response relation, we performed a curve
fit regression analysis to test linear, quadratic, and exponential
dependencies (independent variable: isoflurane concentration;
dependent variable: TUNEL intensity or Bax/Bcl-2 protein
expression, respectively). This explorative approach has been
utilized to make sure to detect both linear and complex
dependencies. The best fit in terms of R
2 is reported. For the
TUNEL data, only the regression analysis was performed.
Differences were considered significant if P#0.05. Values are
expressed as median 6 interquartile ranges.
Results
TEER Measurements
During growth of the freshly seeded HUVECs, the TEER
increased until it reached a maximum on Day 3–4, after which the
TEER began to decline gradually. The ACM treatment almost
doubled the maximum specific TEER to values slightly above
600 Vcm
2 (data not shown). All isoflurane and hypoxia experi-
ments started on Day 4.
No Hypoxia
TUNEL assay and microscopy. Fluorescence levels in the
AC-HUVECs, demonstrated by TUNEL staining, exhibited a dose
dependency, up to a 2.5-fold increase, which was best described
using a quadratic regression model, both after 4 h (R
2=0.91,
P=0.003) and 24 h (R
2=0.95, P,0.001)(Figure 2A). Microscopic
analysis performed 4 h after isoflurane exposure still showed
a confluent layer of visually normal cell bodies with normal nuclei,
similar to those seen in the untreated control group. After 24 h
following isoflurane treatment, gaps occurred in the cell layer
along with a stronger condensation of nuclei, and there was
budding at cell boundaries, irrespective of which isoflurane
concentration had been applied (data not shown).
Bax and Bcl-2. In experiments not involving hypoxic
challenge, isoflurane exposure up to 1 MAC did not lead to
significant changes in Bax protein levels in the overall comparison
at 4 h posttreatment compared to baseline (P=0.08, Kruskal-
Wallis test). However, at 2 MAC we did observe a significant
increase in the Bax level over baseline (104634 arbitrary units
(AU) vs. 62637 AU, P=0.05, Mann-Whitney test; Figure 3A).
Thus, a weak linear dose-response relationship was present
(R
2=0.44, P=0.02, Figure 4A). In contrast, after 24 h there
were significant changes in Bax levels compared to baseline
(P=0.02), with an increase after treatment with 0.5 MAC
isoflurane (80623 AU vs. 51627 AU, P=0.05) and a decrease
in Bax levels in the 1-MAC and 2-MAC groups to 1766 AU and
2162 AU, respectively (control: 51627 AU, P=0.05, Figure 3A).
There was no linear or quadratic dependency in the regression
analysis (Figure 4B).
The anti-apoptotic marker Bcl-2 was observed to have an early
increase in protein levels from 58624 AU (control) to
1456118 AU, 193659 AU, and 320668 AU in response to
rising isoflurane concentrations (P=0.02 in the global Kruskal-
Wallis analysis, and P=0.05 for each isoflurane concentration,
Mann-Whitney test, Figure 3B); the increase was concentration
dependent (linear regression: R
2=0.87, P,0.001; Figure 4A). The
significant difference, compared to control cells, was lost at the 24-
hour time point (P=0.09, Kruskal-Wallis test) as was the
concentration dependency (R
2=0.27, P=0.82; Figure 4B).
Hypoxia
TUNNEL assay and microscopy. TUNEL intensity in-
creased almost 2-fold at high isoflurane concentrations (2 MAC)
4 h posttreatment and increased further to as much as 8 times
baseline at 24 h. A quadratic equation fit the data best (R
2=0.75,
P=0.031 at 4 h, and R
2=0.98, P,0.001 at 24 h, Figure 2B).
Microscopic examination of AC-HUVECs exposed to normoxic
conditions (controls) revealed normal cell shapes, morphological
characteristics, and confluence. Similarly, after 4 h of recovery
from isoflurane exposure and hypoxia the cells appeared un-
remarkable. In contrast, 24 h after exposure to isoflurane and
hypoxia we could detect multiple interruptions of the cell layer,
condensations of nuclei, and budding at cell boundaries in the cell
layer. These effects were greatest in the 2-MAC isoflurane group,
Figure 1. Study Protocol. Diagram of the study setup displaying the time course of experimental interventions performed on transdifferentiated
AC-HUVEC.
doi:10.1371/journal.pone.0038260.g001
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TUNEL fluorescence increased with rising isoflurane concentra-
tions (Figure 5).
Bax and Bcl-2. In AC-HUVECs that had been rendered
hypoxic before isoflurane treatment, Bax expression differed
significantly from that of isoflurane-naı ¨ve control cells, both after
4 and 24 h of latency (P=0.02, Kruskal-Wallis test respectively).
There were increases in Bax levels in the early group, from
56628 AU (control conditions) to 180656 AU (1 MAC) and
1816116 AU (2 MAC), with an intermediate decrease in the Bax
level at 0.5 MAC (41618 AU; P=0.05 for each group, Figure 3A).
In the curve fit analysis, the correlation could best be described by
a quadratic model (R
2=0.71, P=0.004, Figure 4C). At 24 h after
isoflurane exposure we found a similar expression pattern:
subsequent to a decrease in the Bax level at a low dose
(0.5 MAC) of isoflurane (3966 AU vs. 58646 AU for control),
increases in Bax levels were detected for higher isoflurane
concentrations (10965 AU at 1 MAC and 16163A U a t
2 MAC, P=0.05 respectively, Figure 3A). Again, a quadratic
regression was the best fit (R
2=0.80, P=0.001, Figure 4D).
Compared to Bax expression, Bcl-2 expression behaved in an
almost inverse manner: After both 4 and 24 h, increases in Bcl-2
levels were observed in cells treated with 0.5 MAC compared to
control cells (145634 AU vs. 71627 AU after 4 h; 126666 AU
vs. 41612 AU after 24 h; P=0.05, Mann-Whitney test). With
increasing concentrations of isoflurane, however, Bcl-2 levels
decreased (at 4 h: 1006226 AU at 1 MAC [n.s.] and 36621 AU
at 2 MAC [P=0.05] vs. control, Mann-Whitney test, Figure 4C;
after 24 h: 29617 AU at 1 MAC [n.s.] and 1862 AU at 2 MAC,
P=0.05, Figure 3B). For both time points the global statistical
comparison confirmed the differences (P=0.04 and 0.02, re-
spectively, Kruskal-Wallis test). In the curve fit analysis, only at
24 h was a weak exponential dose-response relationship detectable
(R
2=0.39, P=0.03, Figure 4D).
Discussion
Inthisstudyweinvestigatedtheinfluenceofthevolatileanesthetic
agent isoflurane on AC-HUVECs, a well-established in vitro model
used in BBB studies. We could show a delayed and dose-dependent
increase in the pro-apoptic marker Bax and a decrease in the anti-
apoptoticmarkerBcl-2.Ourobservationswerefurthersupportedby
TUNEL staining and by morphological assessment, confirming the
presenceofincreasedapoptosis.Thisfindingisimportantforclinical
anesthesiology and also for experimental research, especially in
investigations of CNSdiseases suchas stroke.
For many years, stroke research focused on neuronal pathology
and neuroprotection, yet did not result in clinically beneficial
neuroprotective regimens. Recently, a more holistic approach has
been introduced, shifting interest from neurons toward the
neurovascular unit (NVU) [1]. In the NVU concept, interaction
between neurons, astrocytes, microglia, pericytes and endotheli-
um, the latter forming the main component of the BBB, occur,
ultimately affecting neurological outcome in this primarily vascular
disorder. One of the most important pathophysiological con-
sequences of cerebral ischemia is the loss of barrier function of the
BBB (often referred to as disruption or leakage). This effect
comprises not only loss of tight junction function but also
degradation of basal lamina matrix proteins and alterations of
the glia limitans formed by astrocyte end feet [19]. BBB leakage
following cerebral ischemia in humans can be observed from 3 h
to 7 days [20] and, on the endothelial level, is dependent on the
destabilization of the tight junction complex and consecutively the
para-endothelial influx of low-molecular-weight contrast agents up
to large molecules such as albumin [21].
In experimental stroke research, BBB disruption has shown to be
a highly dynamic process, as first described by Olsson et al. in 1971
[22], and at least two distinct BBB openings to contrast agents such
as Evans blue and [3 H] sucrose have been demonstrated
[22,23,24]. The molecular basis of increased BBB permeability
comprises alterations in the expression of tight-junction related
proteins and conforming changes of tight junction proteins within
the cell membranes, especially occludin, claudin-2 and claudin-5.
This can be achieved via a large variety of pathways. Chemokines,
excitatory amino acids, and matrix metalloproteinases (MMP) are
only some important candidates induced by ischemia and released
by pericytes, astroglia and inflammatory cells [19,25]. In rats it has
been demonstrated that acute astrocyte loss can induce reversible
loss of the normal para-cellular localization of the transmembrane
proteins occludin and claudin-5 and cytoplasmic ZO-1, which
Figure 2. TUNEL Regression Analysis. Quantification and quadratic
regression analysis of TUNEL fluorescence in relation to hypoxia,
isoflurane concentrations, and delay to analysis subsequent to 2 hours
of isoflurane exposure. a) No hypoxia. 4-hour latency period: R
2=0.91,
P=0.003; 24-hour latency period: R
2=0.95, P,0.001. b) Hypoxia for 24
hours followed by 2 hours of reoxygenation prior to isoflurane
treatment. 4-hour latency period: R
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tightjunctions,changesintransendothelialfluxandlossofstructural
support due to basal membrane and extracellular matrix degrada-
tion [25,26,27].
The concept of biphasic opening of the BBB has been
demonstrated after focal ischemia/reperfusion, with early short-
lasting para-endothelial leakage within the first 4 to 6 h, partial
closure at 24 h, and a delayed long-lasting opening that begins
with a peak at 48 h [12]. The latter may last up to 1 month,
depending on the length and severity of the ischemia [28].
Abrogation of BBB leakage by blocking MMPs in the early phase
has proved to be beneficial, whereas delayed treatment worsens
outcome [5,29]. Thus, the timing of an intervention needs to be
included as a parameter in the scope of stroke investigations to
a much greater extent than it was in the past.
Numerous studies on the volatile anesthetic agent isoflurane and
its effect on the pathophysiology of focal cerebral ischemia when
administered during the ischemic period have produced conflict-
ing results [30,31,32,33,34,35,36,37,38,39]. However, there is
a lack of sufficient data on the influence of isoflurane when
administration is delayed until the reperfusion period. In the early
post-ischemic phase the volatile anesthetic might exert a neuro-
protective effect, referred to as postconditioning, by activating the
sphingosine-1-phosphate/phosphatidylinositol-3-kinase/Akt path-
way [40] or by interfering with mitochondrial adenosine 59-
triphosphate–sensitive potassium channels [41]. Tertrault et al., on
the other hand, published a paper in which isoflurane treatment of
healthy cat brains resulted in extravasation of Evans blue [7]. In
a rat model of transient middle cerebral artery occlusion,
isoflurane worsens not only infarct volume, but also brain edema
and hemorrhagic transformation if applied for one hour imme-
diately after reperfusion [13], which supports the notion of
isoflurane mediated cerebro-vascular injury.
Isoflurane is known to promote the neuronal expression of Bcl-2,
whichisasupposedmechanismofitsneuroprotectiveeffect[38,39].
In contrast, in this study we were able to demonstrate that exposure
to isoflurane in clinically relevant concentrations leads to a dose-
dependent shift in endothelial Bax and Bcl-2 protein expression,
followed by an increase in delayed apoptosis in AC-HUVECs.
These changes were potentiated by hypoxia prior to isoflurane
Figure 3. Bax/Bcl-2 Western Blot bar graphs. Median value and interquartile range of Bax (a) and Bcl-2 (b) protein expression in relation to
hypoxic challenge and recovery period (4/24 h). N.s.: not significant, *: statistically significant difference to control/0 MAC in Mann-Whitney test.
doi:10.1371/journal.pone.0038260.g003
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apoptoticBcl-2behaved inacomplexpattern.Bcl-2showedadose-
dependent, timely limited increase in expression under normoxic
conditions (Figures 3B, 4A, and 4B), but a delayed down regulation
with increasing isoflurane concentrations in posthypoxic cells
(Figures 3B, 4D). Its counterpart Bax, on the other hand, was only
slightly influenced by exposure to the anesthetic agent as long as the
endothelium was not rendered hypoxic. After hypoxia, Bax levels
rose substantially in parallel with isoflurane dosing. Thus, in
posthypoxic AC-HUVECs in which there was a 24-hour latency
period subsequent to isoflurane treatment (Figures 3, 4D), Bax and
Bcl-2 displayed inverse behaviors, favoring the development of
apoptosis,which,inturn,manifestedinDNAdegradationattheend
stage of apoptosis, as demonstrated using TUNEL staining and
morphological observations.
These findings have several implications. Neurons and endo-
thelial cells could be affected by postischemic isoflurane exposure
in an opposite fashion. Although neurons seem to be protected by
isoflurane [38,39,40,41], cerebral endothelial cells forming the
BBB may be severely injured. This stresses the importance of
a taking a holistic view on the effects of peri-ischemic interventions
to the brain. Secondly, the role of isoflurane in CNS research has
to be re-evaluated: if isoflurane proves to have a profound
influence on BBB integrity, its usefulness in stroke research must
be questioned. Last, but not least, isoflurane is a popular anesthetic
agent in patient care. Despite the vast clinical usage and well-
established safety profile of the drug, there may be certain
circumstances that we are currently not aware of in which
isoflurane should be replaced. If the results of our study hold true
in further experimental approaches and also in the clinical setting,
it may be best if patients at risk for cerebral edema, like after brain
trauma or during carotid desobliteration, receive an alternative
hypnotic compound to perform general anesthesia.
Study Limitations
This study was performed on an in vitro model of the BBB, in
which human umbilical cells were transdifferentiated to a cerebro-
vascular phenotype by astrocyte conditioned culture medium, and
kept without contact to their natural cellular environment
(neurons, pericytes, blood etc.). Thus, their behavior not neces-
sarily reflects the in vivo situation. Since the analysis was restricted
to two distinct time points, important phenomena which
manifested outside the observational time window might have
been missed. In addition, case numbers were low, rendering
a certain extent of uncertainty to the statistical analysis and
establishing the need for further experimental confirmation.
In summary, isoflurane has a profound influence on endothelial
cells within the first day after sustained hypoxia in an in vitro
model of the BBB, were it induces endothelial apoptosis in
a delayed, dose-dependent manner. Therefore this anesthetic
agent should be avoided in in vitro experiments focusing on
Figure 4. Bax/Bcl-2 Western Blot Curve Fit Analysis. Western blot
data and curve fit of Bax (drawn as crosses and dashed lines) and Bcl-2
(rings, solid lines) in relation to hypoxia, isoflurane concentration, and
delay to analysis subsequent to 2 hours of isoflurane exposure. a) No
hypoxia. 4-hour latency period: significant positive linear isoflurane
concentration dependency for both Bax (R
2=0.44, P=0.02) and Bcl-2
(R
2=0.87, P,0.001). b) No hypoxia, 24-hour latency period: no
significant concentration dependency. c & d) Hypoxia for 24 hours
followed by 2 hours of reoxygenation prior to isoflurane treatment. c) 4-
hour latency period: positive quadratic dose dependency for Bax
(R
2=0.71, P=0.004); d) 24-hour latency period: positive quadratic dose
dependency for Bax (R
2=0.80, P=0.001) and negative exponential
dependency for Bcl-2 (R
2=0.39, P=0.03).
doi:10.1371/journal.pone.0038260.g004
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conducted to clarify whether the following are the case: i) other
volatile anesthetic agents have similar effects on the BBB; ii) timing
of anesthesia is relevant (i.e. whether there is a vulnerable interval)
after cerebral ischemia; and iii) the isoflurane effect on the BBB is
relevant to outcome after cerebral ischemia in vivo.
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